Researchers at Beth Israel Deaconess Medical Center (BIDMC) reported that proactive monitoring of dose adjustments of infliximab (IFX), one of the 4 anti-TNF-alpha proteins used to treat inflammatory diseases like Crohn’s disease (CD), ulcerative colitis (UC), and inflammatory bowel disease (IBD), could prolong the effectiveness of treatment.
Experts have discovered a possible correlation between treatment with isotretinoin and decreased risk of inflammatory bowel disease, according to a study published in the Journal of American Medical Association Dermatology.
A research team with members at the University of California, Los Angeles (UCLA) has discovered genetic factors involved in a severe form of inflammatory bowel disease (IBS), pediatric ulcerative colitis.
Patients with irritable bowel syndrome experience less effective pain treatments, according to research from the University of Adelaide in Australia.
Researchers at the University of Leicester have developed a highly sensitive “electronic-nose” to identify the infectious bacteria Clostridium difficile that causes diarrhea, stomach cramps, and fever in patients.
Monitoring patients’ own intestinal immune responses, researchers at Yale University have identified some of the bacterial culprits driving inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis.